Search

Your search keyword '"Calleri, Angelica"' showing total 224 results
Start Over Author "Calleri, Angelica"
224 results on '"Calleri, Angelica"'

1. The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade

Author

Tabanelli, Valentina, Melle, Federica, Motta, Giovanna, Mazzara, Saveria, Fabbri, Marco, Agostinelli, Claudio, Calleri, Angelica, Del Corvo, Marcello, Fiori, Stefano, Lorenzini, Daniele, Cesano, Alessandra, Chiappella, Annalisa, Vitolo, Umberto, Derenzini, Enrico, Griffin, Gabriel K., Rodig, Scott J., Vanazzi, Anna, Sabattini, Elena, Tarella, Corrado, Sapienza, Maria Rosaria, and Pileri, Stefano A.

Published
2022
Full Text
View/download PDF

2. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

Author

Rossi, Alessandra, Orecchioni, Stefania, Falvo, Paolo, Tabanelli, Valentina, Baiardi, Elena, Agostinelli, Claudio, Melle, Federica, Motta, Giovanna, Calleri, Angelica, Fiori, Stefano, Corsini, Chiara, Casadei, Beatrice, Mazzara, Saveria, Vitolo, Umberto, Bertolini, Francesco, Zinzani, Pier Luigi, Alcalay, Myriam, Pelicci, Pier Giuseppe, Pileri, Stefano, Tarella, Corrado, and Derenzini, Enrico

Published
2022
Full Text
View/download PDF

4. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified

Author

Laginestra, Maria Antonella, Cascione, Luciano, Motta, Giovanna, Fuligni, Fabio, Agostinelli, Claudio, Rossi, Maura, Sapienza, Maria Rosaria, Righi, Simona, Broccoli, Alessandro, Indio, Valentina, Melle, Federica, Tabanelli, Valentina, Calleri, Angelica, Novero, Domenico, Facchetti, Fabio, Inghirami, Giorgio, Sabattini, Elena, Bertoni, Francesco, and Pileri, Stefano A.

Published
2020
Full Text
View/download PDF

5. Mediastinal Gray-Zone Lymphoma: Still an Open Issue

Author

Pileri, Stefano, primary, Tabanelli, Valentina, additional, Chiarle, Roberto, additional, Calleri, Angelica, additional, Melle, Federica, additional, Motta, Giovanna, additional, Sapienza, Maria Rosaria, additional, Sabattini, Elena, additional, Zinzani, Pier Luigi, additional, and Derenzini, Enrico, additional

Published
2023
Full Text
View/download PDF

6. Gray-Zone Lymphoma: A Still Open Issue

Author

Pileri, Stefano, primary, Tabanelli, Valentina, additional, Roberto, Chiarle, additional, Calleri, Angelica, additional, Melle, Federica, additional, Motta, Giovanna, additional, Sapienza, Maria Rosaria, additional, Sabattini, Elena, additional, Zinzani, Pier Luigi, additional, and Derenzini, Enrico, additional

Published
2023
Full Text
View/download PDF

11. Supplementary Figure Legends and Tables from Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer

Author

Orecchioni, Stefania, primary, Gregato, Giuliana, primary, Martin-Padura, Ines, primary, Reggiani, Francesca, primary, Braidotti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Quarna, Jessica, primary, Marighetti, Paola, primary, Aldeni, Chiara, primary, Pruneri, Giancarlo, primary, Martella, Stefano, primary, Manconi, Andrea, primary, Petit, Jean-Yves, primary, Rietjens, Mario, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures from Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer

Author

Orecchioni, Stefania, primary, Gregato, Giuliana, primary, Martin-Padura, Ines, primary, Reggiani, Francesca, primary, Braidotti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Quarna, Jessica, primary, Marighetti, Paola, primary, Aldeni, Chiara, primary, Pruneri, Giancarlo, primary, Martella, Stefano, primary, Manconi, Andrea, primary, Petit, Jean-Yves, primary, Rietjens, Mario, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

13. Data from The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression

Author

Martin-Padura, Ines, primary, Gregato, Giuliana, primary, Marighetti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Corsini, Chiara, primary, Pruneri, Giancarlo, primary, Manzotti, Michela, primary, Lohsiriwat, Visnu, primary, Rietjens, Mario, primary, Petit, Jean-Yves, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Video 1 from The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression

Author

Martin-Padura, Ines, primary, Gregato, Giuliana, primary, Marighetti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Corsini, Chiara, primary, Pruneri, Giancarlo, primary, Manzotti, Michela, primary, Lohsiriwat, Visnu, primary, Rietjens, Mario, primary, Petit, Jean-Yves, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

15. Data from Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer

Author

Orecchioni, Stefania, primary, Gregato, Giuliana, primary, Martin-Padura, Ines, primary, Reggiani, Francesca, primary, Braidotti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Quarna, Jessica, primary, Marighetti, Paola, primary, Aldeni, Chiara, primary, Pruneri, Giancarlo, primary, Martella, Stefano, primary, Manconi, Andrea, primary, Petit, Jean-Yves, primary, Rietjens, Mario, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression

Author

Martin-Padura, Ines, primary, Gregato, Giuliana, primary, Marighetti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Corsini, Chiara, primary, Pruneri, Giancarlo, primary, Manzotti, Michela, primary, Lohsiriwat, Visnu, primary, Rietjens, Mario, primary, Petit, Jean-Yves, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure Legends 1-5, Movie Legend 1 from The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression

Author

Martin-Padura, Ines, primary, Gregato, Giuliana, primary, Marighetti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Corsini, Chiara, primary, Pruneri, Giancarlo, primary, Manzotti, Michela, primary, Lohsiriwat, Visnu, primary, Rietjens, Mario, primary, Petit, Jean-Yves, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figures 1-5 from The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression

Author

Martin-Padura, Ines, primary, Gregato, Giuliana, primary, Marighetti, Paola, primary, Mancuso, Patrizia, primary, Calleri, Angelica, primary, Corsini, Chiara, primary, Pruneri, Giancarlo, primary, Manzotti, Michela, primary, Lohsiriwat, Visnu, primary, Rietjens, Mario, primary, Petit, Jean-Yves, primary, and Bertolini, Francesco, primary

Published
2023
Full Text
View/download PDF

20. Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

Author

Leupin, Nicolas, Zinzani, Pier Luigi, Morschhauser, Franck, Dalle, Stephane, Maerevoet, Marie, Michot, Jean-Marie, Ribrag, Vincent, Offner, Fritz, Beylot-Barry, Marie, Moins-Teisserenc, Helene, Zwaenepoel, Karen, De Winne, Koen, Battistella, Maxime, Hultberg, Anna, Gandini, Domenica, Moshir, Mahan, Jacobs, Julie, Delahaye, Tim, Khan, Aitzaz, Zabrocki, Piotr, Silence, Karen, van Rompaey, Luc, Borg, Christophe, Motta, Giovanna, Melle, Federica, Calleri, Angelica, Pauwels, Patrick, de Haard, Hans, Pileri, Stefano, Bagot, Martine, and de Winne, Koen

Subjects
Cancer Research, medicine.medical_specialty, Skin Neoplasms, Antineoplastic Agents, Gastroenterology, Pharmacokinetics, Refractory, Internal medicine, medicine, Humans, Adverse effect, business.industry, Immunogenicity, Cutaneous T-cell lymphoma, Antibodies, Monoclonal, medicine.disease, Lymphoma, T-Cell, Cutaneous, Lymphoma, Clinical trial, Treatment Outcome, Oncology, Human medicine, Neoplasm Recurrence, Local, Vasculitis, business, CD27 Ligand
Abstract

Background The clinical benefit of cusatuzumab, a CD70-directed monoclonal antibody with enhanced effector functions, was investigated in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL). Methods In this cohort expansion of the ARGX-110-1201 study, 27 patients with R/R CTCL received cusatuzumab at 1 (n = 11) or 5 mg/kg (n = 16) once every 3 weeks to investigate its safety, dose, and exploratory efficacy. The pharmacokinetics, immunogenicity, CD70 expression, and CD70/CD27 biology were also assessed. Results The most common adverse events included infusion-related reactions, pyrexia, and asthenia. Eighteen serious adverse events (grade 1-3) were reported in 11 patients; 1 of these (vasculitis) was considered drug-related. For 8 of the 11 patients receiving 1 mg/kg, anti-drug antibodies (ADAs) affected the minimal concentration, and this resulted in undetectable cusatuzumab concentrations at the end of treatment and, in some cases, a loss of response. This effect was greatly reduced in the patients receiving 5 mg/kg. The overall response rate was 23%; this included 1 complete response and 5 partial responses (PRs) in 26 of the 27 evaluable patients. In addition, 9 patients achieved stable disease. The mean duration on cusatuzumab was 5.2 months, and the median duration was 2.5 months. Patients with Sezary syndrome (SS) achieved a 60% PR rate with a dosage of 5 mg/kg and a 33% PR rate with a dosage of 1 mg/kg; this resulted in an overall response rate of 50% for patients with SS at both doses. Conclusions Cusatuzumab was well tolerated, and antitumor activity was observed at both 1 and 5 mg/kg in highly pretreated patients with R/R CTCL. The observed dose-dependent effect on exposure supports the use of 5 mg/kg for future development.

Published
2021

22. Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified

Author

Laginestra, Maria Antonella, Cascione, Luciano, Motta, Giovanna, Fuligni, Fabio, Agostinelli, Claudio, Rossi, Maura, Sapienza, Maria Rosaria, Righi, Simona, Broccoli, Alessandro, Indio, Valentina, Melle, Federica, Tabanelli, Valentina, Calleri, Angelica, Novero, Domenico, Facchetti, Fabio, Inghirami, Giorgio, Sabattini, Elena, Bertoni, Francesco, and Pileri, Stefano A.

Published
2020
Full Text
View/download PDF

23. Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes

Author

Cella, Chiara Alessandra, primary, Spada, Francesca, additional, Berruti, Alfredo, additional, Bertolini, Francesco, additional, Mancuso, Patrizia, additional, Barberis, Massimo, additional, Pisa, Eleonora, additional, Rubino, Manila, additional, Gervaso, Lorenzo, additional, Laffi, Alice, additional, Pellicori, Stefania, additional, Radice, Davide, additional, Zorzino, Laura, additional, Calleri, Angelica, additional, Funicelli, Luigi, additional, Petralia, Giuseppe, additional, and Fazio, Nicola, additional

Published
2022
Full Text
View/download PDF

28. A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma

Author

Derenzini, Enrico, Mazzara, Saveria, Melle, Federica, Motta, Giovanna, Fabbri, Marco, Bruna, Riccardo, Agostinelli, Claudio, Cesano, Alessandra, Corsini, Chiara Antonia, Chen, Ning, Righi, Simona, Sabattini, Elena, Chiappella, Annalisa, Calleri, Angelica, Fiori, Stefano, Tabanelli, Valentina, Cabras, Antonello, Pruneri, Giancarlo, Vitolo, Umberto, Gianni, Alessandro Massimo, Rambaldi, Alessandro, Corradini, Paolo, Zinzani, Pier Luigi, Tarella, Corrado, and Pileri, Stefano

Subjects
Proto-Oncogene Proteins c-myc, NF-KappaB Inhibitor alpha, Proto-Oncogene Proteins c-bcl-2, Gene Expression Profiling, Antineoplastic Combined Chemotherapy Protocols, Proto-Oncogene Proteins c-bcl-6, Humans, Lymphoma, Large B-Cell, Diffuse, Prognosis, Risk Assessment, Article
Abstract

Recent randomized trials focused on gene expression-based determination of the cell of origin in diffuse large B-cell lymphoma could not show significant improvements by adding novel agents to standard chemoimmunotherapy. The aim of this study was the identification of a gene signature able to refine current prognostication algorithms and applicable to clinical practice. Here we used a targeted gene expression profiling panel combining the Lymph2Cx signature for cell of origin classification with additional targets including MYC, BCL-2 and NFKBIA, in 186 patients from two randomized trials (discovery cohort) (clinicaltrials gov. Identifier: NCT00355199 and NCT00499018). Data were validated in three independent series (two large public datasets and a real-life cohort). By integrating the cell of origin, MYC/BCL-2 double expressor status and NFKBIA expression, we defined a three-gene signature combining MYC, BCL-2 and NFKBIA (MBN-signature), which outperformed the MYC/BCL-2 double expressor status in multivariate analysis, and allowed further risk stratification within the germinal center B-cell/unclassified subset. The high-risk (MBN Sig-high) subgroup identified the vast majority of double hit cases and a significant fraction of activated B-cell-derived diffuse large B-cell lymphomas. These results were validated in three independent series including a cohort from the REMoDL-B trial, where, in an exploratory ad hoc analysis, the addition of bortezomib in the MBN Sig-high subgroup provided a progression free survival advantage compared with standard chemoimmunotherapy. These data indicate that a simple three-gene signature based on MYC, BCL-2 and NFKBIA could refine the prognostic stratification in diffuse large B-cell lymphoma, and might be the basis for future precision-therapy approaches.

Published
2020

30. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

Author

Rossi, Alessandra, primary, Orecchioni, Stefania, additional, Falvo, Paolo, additional, Tabanelli, Valentina, additional, Baiardi, Elena, additional, Agostinelli, Claudio, additional, Melle, Federica, additional, Motta, Giovanna, additional, Calleri, Angelica, additional, Fiori, Stefano, additional, Corsini, Chiara, additional, Casadei, Beatrice, additional, Mazzara, Saveria, additional, Vitolo, Umberto, additional, Bertolini, Francesco, additional, Zinzani, Pier Luigi, additional, Alcalay, Myriam, additional, Pelicci, Pier Giuseppe, additional, Pileri, Stefano, additional, Tarella, Corrado, additional, and Derenzini, Enrico, additional

Published
2021
Full Text
View/download PDF

33. The identification of TCF1+progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade

Author

Tabanelli, Valentina, Melle, Federica, Motta, Giovanna, Mazzara, Saveria, Fabbri, Marco, Agostinelli, Claudio, Calleri, Angelica, Del Corvo, Marcello, Fiori, Stefano, Lorenzini, Daniele, Cesano, Alessandra, Chiappella, Annalisa, Vitolo, Umberto, Derenzini, Enrico, Griffin, Gabriel K., Rodig, Scott J., Vanazzi, Anna, Sabattini, Elena, Tarella, Corrado, Sapienza, Maria Rosaria, and Pileri, Stefano A.

Abstract

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare and aggressive variant of diffuse large B-cell lymphoma (DLBCL) that usually affects young to middle-aged patients, with disseminated disease at presentation. The tumor microenvironment (TME) plays a key role in THRLBCL due to its peculiar cellular composition (<10% neoplastic B cells interspersed in a cytotoxic T-cell/histiocyte-rich background). A significant percentage of THRLBCL is refractory to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)-based regimens and to chimeric antigen receptor T-cell therapy; thus, the development of a specific therapeutic approach for these patients represents an unmet clinical need. To better understand the interaction of immune cells in THRLBCL TME and identify more promising therapeutic strategies, we compared the immune gene expression profiles of 12 THRLBCL and 10 DLBCL samples, and further corroborated our findings in an extended in silico set. Gene coexpression network analysis identified the predominant role of the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis in the modulation of the immune response. Furthermore, the PD-1/PD-L1 activation was flanked by the overexpression of 48 genes related to the functional exhaustion of T cells. Globally, THRLBCL TME was highly interferon-inflamed and severely exhausted. The immune gene profiling findings strongly suggest that THRLBCL may be responsive to anti–PD-1 therapy but also allowed us to take a step forward in understanding THRLBCL TME. Of therapeutic relevance, we validated our results by immunohistochemistry, identifying a subset of TCF1+(T cell–specific transcription factor 1, encoded by the TCF7gene) progenitor exhausted T cells enriched in patients with THRLBCL. This subset of TCF1+exhausted T cells correlates with good clinical response to immune checkpoint therapy and may improve prediction of anti–PD-1 response in patients with THRLBCL.

Published
2022
Full Text
View/download PDF

36. Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma

Author

Tabanelli, Valentina, primary, Melle, Federica, additional, Motta, Giovanna, additional, Mazzara, Saveria, additional, Fabbri, Marco, additional, Corsini, Chiara, additional, Gerbino, Elvira, additional, Calleri, Angelica, additional, Sapienza, Maria Rosaria, additional, Abbene, Ignazio, additional, Stufano, Viviana, additional, Barberis, Massimo, additional, and Pileri, Stefano A., additional

Published
2020
Full Text
View/download PDF

40. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant–associated anaplastic large cell lymphomas

Author

Tabanelli, Valentina, primary, Corsini, Chiara, additional, Fiori, Stefano, additional, Agostinelli, Claudio, additional, Calleri, Angelica, additional, Orecchioni, Stefania, additional, Melle, Federica, additional, Motta, Giovanna, additional, Rotili, Anna, additional, Di Napoli, Arianna, additional, and Pileri, Stefano A., additional

Published
2019
Full Text
View/download PDF

42. Dissecting diffuse large B-cell lymphomas of the “not otherwise specified” type: the impact of molecular techniques

Author

Pileri, Stefano A, primary, Derenzini, Enrico, additional, Melle, Federica, additional, Motta, Giovanna, additional, Calleri, Angelica, additional, Antoniotti, Pierluigi, additional, Maltoni, Virginia, additional, Spagnolo, Sebastiano, additional, Fiori, Stefano, additional, Tabanelli, Valentina, additional, and Fabbri, Marco, additional

Published
2018
Full Text
View/download PDF

43. Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Author

Bagot, Martine, primary, Maerevoet, Marie, additional, Zinzani, Pier Luigi, additional, Offner, Fritz, additional, Morschhauser, Franck, additional, Michot, Jean-Marie, additional, Ribrag, Vincent, additional, Battistella, Maxime, additional, Moins, Helene, additional, Calleri, Angelica, additional, Dalle, Stéphane, additional, Beylot-Barry, Marie, additional, Zwaenepoel, Karen, additional, De Winnie, Koen, additional, Marie-Cardine, Anne, additional, Cayuela, Jean-Michel, additional, Tabanelli, Valentina, additional, Motta, Giovanna, additional, Melle, Federica, additional, Hultberg, Anna, additional, Gandini, Domenica, additional, Marafioti, Teresa, additional, Moshir, Mahan, additional, Delahaye, Tim, additional, Zabrocki, Piotr, additional, Silence, Karen, additional, Van Rompaey, Luc, additional, Bensussan, Armand, additional, De Haard, Hans, additional, Pauwels, Patrick, additional, Leupin, Nicolas, additional, and Pileri, Stefano A., additional

Published
2018
Full Text
View/download PDF

44. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma

Author

Pruneri Giancarlo, Quarna Jessica, Antoniotti Pierluigi, Calleri Angelica, Mancuso Patrizia, and Bertolini Francesco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Staging of B-cell non Hodgkin's lymphoma (NHL) routinely involves bone marrow (BM) examination by trephine biopsy (BM-TB). The evidence of disease in the BM-TB results in a clinical stage IV classification affecting therapeutic strategies for NHL patients. BM immunophenotyping by flow cytometry (FC) is also used, although its clinical value is still under debate. Methods Using FC we analyzed 1,000 paired BM aspirates and peripheral blood (PB) samples from 591 NHL patients to investigate the concordance between BM and PB. B-lymphocytes were defined monoclonal when a ratio of 0.3 < κ/l > 3 was observed. Aberrant immunophenotypes present in the B-cell subpopulation were also investigated. BM-TB was also performed in 84.1% of samples (841/1000), and concordance between BM-TB and BM-FC was evaluated. Concordance was defined as the presence of a positive (in terms of disease detection) or negative result in both BM-FC and PB-FC or BM-TB and BM-FC. Results Using FC, the overall concordance between BM and PB was 95%. Among the discordant cases (ie presence of neoplastic B-lymphocyte in the BM but under the sensibility of the technique in the PB) the most frequent diagnosis was Waldenstrom's macroglobulinemia (WM, accounting for 20.8% of all discordant cases). The expression of CXCR4, a receptor involved in B-cell trafficking and homing, was found to be down regulated in WM compared to other NHL types, thus suggesting a possible role of CXCR4 in WM cell homing in the BM. WM excluded, FC investigation of BM and PB in NHL patients gives overlapping information. BM involvement was observed by FC in 38% of samples, and concordance between BM-FC and BM-TB was 85%. Conclusions The finding that FC data from BM and PB samples overlap in NHL might have major implications for the design of future clinical studies and for patients' follow-up.

Published
2010
Full Text
View/download PDF

47. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

Author

Zaja, Francesco, primary, Tabanelli, Valentina, additional, Agostinelli, Claudio, additional, Calleri, Angelica, additional, Chiappella, Annalisa, additional, Varettoni, Marzia, additional, Zinzani, Pier Luigi, additional, Volpetti, Stefano, additional, Sabattini, Elena, additional, Fanin, Renato, additional, and Pileri, Stefano A., additional

Published
2016
Full Text
View/download PDF

48. Whole exome sequencing reveals mutations in FAT1tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified

Author

Laginestra, Maria Antonella, Cascione, Luciano, Motta, Giovanna, Fuligni, Fabio, Agostinelli, Claudio, Rossi, Maura, Sapienza, Maria Rosaria, Righi, Simona, Broccoli, Alessandro, Indio, Valentina, Melle, Federica, Tabanelli, Valentina, Calleri, Angelica, Novero, Domenico, Facchetti, Fabio, Inghirami, Giorgio, Sabattini, Elena, Bertoni, Francesco, and Pileri, Stefano A.

Abstract

Peripheral T-cell lymphoma not otherwise specified represents a diagnostic category comprising clinically, histologically, and molecularly heterogeneous neoplasms that are poorly understood. The genetic landscape of peripheral T-cell lymphoma not otherwise specified remains largely undefined, only a few sequencing studies having been conducted so far. In order to improve our understanding of the genetics of this neoplasm, we performed whole exome sequencing along with RNA-sequencing in a discovery set of 21 cases. According to whole exome sequencing results and mutations previously reported in other peripheral T-cell lymphomas, 137 genes were sequenced by a targeted deep approach in 71 tumor samples. In addition to epigenetic modifiers implicated in all subtypes of T-cell neoplasm (TET2, DNMT3A, KMT2D, KMT2C, SETD2), recurrent mutations of the FAT1tumor suppressor gene were for the first time recorded in 39% of cases. Mutations of the tumor suppressor genes LATS1, STK3, ATM, TP53, and TP63were also observed, although at a lower frequency. Patients with FAT1mutations showed inferior overall survival compared to those with wild-type FAT1. Although peripheral T-cell lymphoma not otherwise specified remains a broad category also on molecular grounds, the present study highlights that FAT1mutations occur in a significant proportion of cases, being provided with both pathogenetic and prognostic impact.

Published
2020
Full Text
View/download PDF

49. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells

Author

Talarico, Giovanna, primary, Orecchioni, Stefania, additional, Dallaglio, Katiuscia, additional, Reggiani, Francesca, additional, Mancuso, Patrizia, additional, Calleri, Angelica, additional, Gregato, Giuliana, additional, Labanca, Valentina, additional, Rossi, Teresa, additional, Noonan, Douglas M., additional, Albini, Adriana, additional, and Bertolini, Francesco, additional

Published
2016
Full Text
View/download PDF

50. Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma – a case report

Author

Gruszka, Alicja M., primary, Rabascio, Cristina, additional, Cannella, Laura, additional, Sammassimo, Simona, additional, Andreola, Giovanna, additional, Gregato, Giuliana, additional, Faretta, Mario, additional, Calleri, Angelica, additional, De Molfetta, Rita, additional, Pruneri, Giancarlo, additional, Bertolini, Francesco, additional, and Alcalay, Myriam, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results